December 28, 2018
Fresenius Medical Care awaiting U.S. Federal Trade Commission decision on NxStage Medical acquisition
Fresenius Medical Care, the world’s largest provider of dialysis products and services, is still in the process of seeking approval by the U.S. Federal Trade Commission (FTC) for its acquisition of NxStage Medical, Inc. (“NxStage”) and therefore now expects the transaction to close in early 2019.
NxStage, which like Fresenius Medical Care North America is headquartered in the Boston, Massachusetts area, was founded in 1998 and has approximately 3,800 employees worldwide. In 2017, NxStage delivered USD 394 million in revenue.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.